Enanta Pharmaceuticals (ENTA) Stock
Biotech company developing antiviral medicines in trials. Here's the price, business snapshot, and what's worth knowing about Enanta Pharmaceuticals in July 2026.
Enanta Pharmaceuticals (ENTA) is a clinical-stage biotechnology company focused on designing and developing small-molecule antiviral therapies. Investors should know the company operates through a pipeline of preclinical and clinical candidates aimed at treating viral illnesses; revenues may be limited while programmes advance. Enanta often seeks partnerships or licensing deals with larger pharmaceutical companies to share development costs and commercialise products. The stock’s market capitalisation is around $306.94M, reflecting investor expectations about future pipeline milestones and licensing potential. Drug development is inherently high-risk and binary — clinical setbacks or regulatory delays can materially affect value, while successful trials or deals can be catalysts. This summary is educational, not personalised investment advice; investors should consider company filings, clinical data, financial position, and their own risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Enanta Pharmaceuticals' stock with a target price of $16, indicating strong potential for growth.
Financial Health
Enanta Pharmaceuticals is generating steady revenue and cash flow, but its overall financial health is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ENTA
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketNext-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and licensing deals can move the share price significantly, though outcomes are uncertain and timelines can be long.
Scientific Focus
Specialises in small-molecule antivirals, which can offer targeted, oral treatment options — but technical and regulatory hurdles remain.
Partnership Potential
Strategic collaborations with larger pharma can fund development and accelerate market access, though terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
